Senti Biosciences Announces $8M CIRM Grant To Support Clinical Development Of SENTI-202 CAR-NK Cell Therapy For Hematologic Malignancies; First Tranche Expected In August 2024; Phase 1 Trial Enrolling Patients In US And Australia, Initial Efficacy Data Anticipated By Year-End 2024
Portfolio Pulse from Benzinga Newsdesk
Senti Biosciences has received an $8M grant from CIRM to support the clinical development of its SENTI-202 CAR-NK cell therapy for hematologic malignancies. The first tranche of the grant is expected in August 2024, with a Phase 1 trial currently enrolling patients in the US and Australia. Initial efficacy data is anticipated by the end of 2024.
August 05, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Senti Biosciences has secured an $8M grant from CIRM to support the clinical development of its SENTI-202 CAR-NK cell therapy. The first tranche is expected in August 2024, with initial efficacy data anticipated by the end of 2024.
The $8M grant from CIRM provides significant financial support for Senti Biosciences' clinical development of SENTI-202, potentially boosting investor confidence. The anticipated initial efficacy data by the end of 2024 could further impact the stock positively if results are favorable.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100